Holen Sie sich die Stockscreener-App
16.65
0.97%
-0.1711
Schlusskurs vom Vortag:
$16.82
Offen:
$16.87
24-Stunden-Volumen:
275.94K
Relative Volume:
0.13
Marktkapitalisierung:
$2.37B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.61M
KGV:
-51.46
EPS:
-0.3235
Netto-Cashflow:
$-45.40M
1W Leistung:
-2.30%
1M Leistung:
-10.01%
6M Leistung:
+42.37%
1J Leistung:
+97.83%
1-Tages-Spanne:
$16.61
$17.02
1-Wochen-Bereich:
$16.47
$17.32
52-Wochen-Spanne:
$7.645
$20.22
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
16.64 | 2.40B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
522.72 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.34 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,003.96 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.54 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.28 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-08-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-07-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair Value - Yahoo Finance
Trevi Therapeutics Stock Price Forecast. Should You Buy TRVI? - StockInvest.us
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
Trevi Therapeutics Inc (TRVI) Peer Comparison – Compare with Others - Value Research
Trevi Therapeutics to Present at Multiple Healthcare and IPF Conferences in September 2026 - Quiver Quantitative
Trevi Therapeutics to Participate in Upcoming September Conferences - Yahoo Finance
Trevi Therapeutics Inc (TRVI) Key Financial Ratios – Valuation, Profitability & More - Value Research
EX-99.1 - SEC.gov
Trevi Therapeutics Inc (TRVI) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 - GlobeNewswire
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI) - Seeking Alpha
$Trevi Therapeutics (TRVI.US)$ lets punch through that BOLL band - Moomoo
Walleye Capital LLC Purchases Shares of 241,987 Trevi Therapeutics, Inc. $TRVI - MarketBeat
TRVI Maintained by Jones Trading -- Price Target Raised to $28.0 - GuruFocus
JonesTrading Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock - MarketBeat
Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)? - simplywall.st
HC Wainwright Issues Pessimistic Estimate for TRVI Earnings - MarketBeat
Sei Investments Co. Has $933,000 Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Inc (TRVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
What is HC Wainwright's Forecast for TRVI FY2030 Earnings? - MarketBeat
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Trevi Therapeutics (TRVI) Short Interest & Short Float | Updated Aug 2026 $TRVI - MarketBeat
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23 - Moomoo
1,525,314 Shares in Trevi Therapeutics, Inc. $TRVI Acquired by Assenagon Asset Management S.A. - MarketBeat
Companies Like Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Invest In Growth - Moomoo
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $23 to $40 - Moomoo
Raymond James Sticks to Its Buy Rating for Trevi Therapeutics (TRVI) - The Globe and Mail
Trevi Therapeutics (TRVI) Receives a New Rating from B. Riley Securities - The Globe and Mail
Q2 2026 Trevi Therapeutics Inc Earnings Call Transcript - GuruFocus
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $25 - Moomoo
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $23 - Moomoo
Trevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates - marketbeat.com
Trevi Therapeutics Q2 Earnings Call Highlights - MarketBeat
Trevi Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.17, Implies 58% Upside - TradingView
Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TRVI Maintains Rating by Oppenheimer -- Price Target Raised to $25.00 - GuruFocus
TRVI Maintains Overweight Rating -- Price Target Raised to $30 b - GuruFocus
Oppenheimer Adjusts Trevi Therapeutics PT to $25 From $24, Maintains Outperform Rating - marketscreener.com
TREVI THERAPEUTICS, INC. : OPPENHEIMER RAISES TARGET PRICE TO $25 FROM $24 - Bitget
Cantor Fitzgerald Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock - marketbeat.com
Raymond James raises Trevi Therapeutics price target on pipeline progress By Investing.com - Investing.com Australia
TRVI SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights - GuruFocus
Earnings call transcript: Trevi Therapeutics posts small Q2 2026 EPS miss - Investing.com UK
Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights: Advancing Phase 3 Pipeline ... - Yahoo Finance
Trevi Therapeutics (TRVI) Advances Clinical Trials Amid High Val - GuruFocus
Trevi Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Trevi Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Trevi Q2 2026 Earnings: Higher Trial Spending Widens the Net Loss - TradingKey
Trevi Therapeutics, Inc. 2Q 2026: Net loss $17.8M, EPS $(0.11) — 10-Q Summary - TradingView
Trevi Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):